

RESPIRONICS INC  
Form 8-K  
March 16, 2007

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

March 16, 2007

**Respironics, Inc.**

(Exact name of registrant as specified in its charter)

Delaware

000-16723

25-1304989

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

1010 Murry Ridge Lane, Murrysville,  
Pennsylvania

15668-8525

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

724-387-5200

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form**

**Item 7.01 Regulation FD Disclosure.**

On March 16, 2007, Respironics, Inc. (the "Company") announced that it has formed an agreement with The State University of New York and New York University School of Medicine to utilize the I-neb Adaptive Aerosol Delivery (AAD®) System for clinical evaluation of aerosolized Interferon Gamma for the treatment of Idiopathic Pulmonary Fibrosis. The clinical trial will take place over a two-year time period.

The Company will not be changing its financial guidance or outlook based on this announcement.

A copy of the press release is attached hereto as Exhibit 99.

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Respironics, Inc.

*March 16, 2007*

By: */s/ Daniel J. Bevevino*

---

*Name: Daniel J. Bevevino*

*Title: Vice President, and Chief Financial and Principal  
Accounting Officer*

---

Edgar Filing: RESPIRONICS INC - Form 8-K

**Top of the Form**

Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
99	Press release, dated March 16, 2007, issued by Respironics, Inc.